This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC).
This study is a retrospective, multicenter cohort study of patients with mPC and reports on genomic testing. Patients were included from 12 academic centers in five countries.
A total of 349 patients with PC were included in this study. Most patients (209, 59.9%) were de novo metastatic. Genomic analysis was performed in 233 (66.6%) patients in the metastatic castration-resistant prostate cancer (mCRPC) setting, and only 115 (32.8%) patients had a tumor evaluation in the metastatic hormone sensitive prostate cancer scenario. The evaluation of somatic and/or germline mutations was performed through multigene panel analyses in 290 (83.09%) patients, and next-generation sequencing of BRCA1 and BRCA2 genes was performed in 59 (16.91%) patients. Analyzing the mCRPC subgroup, with a median follow-up of 15.6 months (IQR, 14-19.06), the median progression-free survival (PFS) was not reached (NR) and the PFS at 16 months was 58.7% (95% CI, 50.8 to 67.8). When comparing patients with BRCA mutations with those who are not BRCA-mutated in the mCRPC scenario, the median PFS was NR (95% CI, 14 to NR) and 26.3 months (95% CI, 16.7 to 36.5; P = .2), respectively. Two of six patients with BRCA mutations were treated with targeted therapies (poly-ADP-ribose polymerase inhibitors).
Our study, to the best of our knowledge, represents one of the larger data sets for somatic testing in patients with PC in Latin America (LATAM). It adds valuable information to the growing body of knowledge about the genomic landscape of advanced PC in real-world daily practice scenarios in LATAM countries, which are not always well-represented in large-scale randomized clinical trials.
JCO global oncology. 2024 Sep 30 [Epub]
Martín Angel, Berenice Freile, Andres Rodriguez, Federico Cayol, Ray Manneh Kopp, Patricia Rioja, Tomas Soule, Federico Losco, Laura Bernal Vaca, Jose Mauricio Penaloza, Maycos Leandro Zapata Muñoz, Silvia Patricia Neciosup, Roger Rodrigo Sanchez, Carolina Passarella, Elvio Guerreño, Diego Farelluk, Ernesto Maturana Leiva, Martin Zarba, Maria Teresa Bourlon, Mauricio Mora Pineda, Juan Pablo Sade
Instituto Alexander Fleming, Buenos Aires, Argentina., Hospital Italiano de Buenos Aires, CABA, Argentina., Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú., Instituto Nacional De Cancerología (Colombia), Bogotá, Colombia., Centro Oncológico Integral, Neuquén, Argentina., Clínica Las Américas Medellín, Antioquia, Colombia., Hospital Militar Central, Buenos Aires, Argentina., Hospital Universitario Austral, Buenos Aires, Argentina., Instituto Misionero del Cáncer, Misiones, Argentina., Instituto del Cáncer Red Salud, Santiago de Chile, Chile., Hospital Centro de Salud Zenón Santillán, Tucumán, Argentina., Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.